Clinical Trial

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 24, 2025 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-16.
Trial Details
NCT Number NCT07082829
Lead Sponsor Centessa Pharmaceuticals (UK) Limited
Conditions Excessive Daytime Sleepiness
Enrollment 208 participants
Start Date 2025-06-30
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-24